No Data
No Data
Noble Financial Sticks to Their Buy Rating for GeoVax Labs (GOVX)
Express News | Update: GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review
Express News | GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review
Express News | GeoVax to Report Second Quarter 2024 Financial Results and Provide Corporate Update on August 6, 2024
Express News | EF Hutton Initiates Coverage On Geovax Labs With Buy Rating, Announces Price Target of $18
Express News | Market-Moving News for July 16th
No Data
NeedsHookerMoney : Might pump a little bit if the Financials are good. That drops on the 6th